Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Total Non-current Liabilities
All obligations due after more than one year.
Alumis Inc. Common StockNASDAQ: ALMS
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities falls 19.5% from a year ago
Total non-current liabilities stood at $32.23M at the end of Q2 FY2026, down 19.5% from a year earlier and down 4.3% from the prior quarter. Over 3 fiscal years it compounded at -49.5% a year.
Context
- Total non-current liabilities amounted to 5.7% of total assets at the end of Q2 FY2026, down 0.8 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -19.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 37.33M USD
- Year-over-year change
- +24.5%
- 3-year CAGR
- -49.5%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.33M | +24.5% |
| FY2024 | 2024-12-31 | 29.98M | -92.7% |
| FY2023 | 2023-12-31 | 408M | +40.7% |
| FY2022 | 2022-12-31 | 290.06M | — |
Total Non-current Liabilities vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -19.5% is the 4th highest of 8, against a peer median of -20.0%.
- Total non-current liabilities amounts to 5.7% of total assets for ALMS, versus a peer median of 5.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $275.24M USD | -20.0% | -3.6% | 83.5% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $32.23M USD | -19.5% | -49.5% | 5.7% |
| Mar 2026 | $27.7M USD | -14.8% | -6.4% | 13.9% | |
| Mar 2026 | $19.97M USD | +94.0% | -2.6% | 20.0% | |
| Mar 2026 | $15.22M USD | -83.2% | -34.8% | 3.0% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €9.19M EUR | — | — | 5.5% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $7.23M USD | -29.7% | -68.3% | 6.8% |
| Mar 2026 | €609.25K EUR | +83.3% | -12.9% | 1.2% | |
| Dec 2025 | $234K USD | — | -1.3% | 2.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -20.0% | -6.4% | 5.5% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.